.jpeg)
2026-03-04 07:32:53
Explore whether Ixazomib (Ninlaro) requires long-term use for Multiple Myeloma. Analyze its critical role in induction and maintenance therapy, the impact of long-term adherence on extending progression-free survival, and expert advice on side effect management and personalized discontinuation strategies.
2026-02-28 06:38:41
Master Regorafenib (Stivarga) dosing: low-fat breakfast, fixed timing, dose escalation strategy for optimal efficacy and reduced side effects in liver and colorectal cancer.
2026-02-28 03:31:21
Isatuximab (Sarclisa) is a CD38-targeting monoclonal antibody approved for relapsed/refractory and newly diagnosed Multiple Myeloma. Its mechanism involves apoptosis induction, ADCC immune killing, and enzymatic inhibition. Clinical data confirms extended Progression-Free Survival (PFS) and improved MRD negativity with combination regimens. This guide covers IV infusion protocols, Infusion-Related Reaction (IRR) management, and patient quality of life insights for optimized treatment decisions.
2026-02-26 03:14:05
Erlotinib,also known as Tarceva,is a classic drug of the epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)family and has a milestone in the precision treatment of lung cancer.Its core indication is non-small cell lung cancer(NSCLC)patients carrying EGFR sensitive mutations.With the advantages of precise targeting and definite efficacy,it effectively breaks the limitations of traditional chemotherapy,promotes the new era of lung cancer treatment from"extensive chemotherapy"to"precise targeting",and brings longer survival and better quality of life to countless advanced lung cancer patients.
2026-02-09 05:42:31
Upatinib (Rift) ®） As an oral JAK inhibitor, it has been approved for various immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, etc. The target population is mainly moderate to severe patients, especially suitable for adults who have insufficient response to traditional treatment, need oral convenience, or have poor injection compliance.
2026-02-09 04:16:06
As an agonist of the thrombopoietin receptor, eltrombopag has significant therapeutic effects in chronic ITP (adults and children), hepatitis C-related thrombocytopenia, and severe aplastic anemia. It can increase platelet count, reduce bleeding risk, assist in antiviral therapy, and promote hematopoietic reconstruction. Clinical data has verified its multi scenario application value.
2026-02-01 22:25:32
